» Articles » PMID: 23407227

Free Tuberculosis Diagnosis and Treatment Are Not Enough: Patient Cost Evidence from Three Continents

Overview
Specialty Pulmonary Medicine
Date 2013 Feb 15
PMID 23407227
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Setting: The National Tuberculosis Programs of Ghana, Viet Nam and the Dominican Republic.

Objective: To assess the direct and indirect costs of tuberculosis (TB) diagnosis and treatment for patients and households.

Design: Each country translated and adapted a structured questionnaire, the Tool to Estimate Patients' Costs. A random sample of new adult patients treated for at least 1 month was interviewed in all three countries.

Results: Across the countries, 27-70% of patients stopped working and experienced reduced income, 5-37% sold property and 17-47% borrowed money due to TB. Hospitalisation costs (US$42-118) and additional food items formed the largest part of direct costs during treatment. Average total patient costs (US$538-1268) were equivalent to approximately 1 year of individual income.

Conclusion: We observed similar patterns and challenges of TB-related costs for patients across the three countries. We advocate for global, united action for TB patients to be included under social protection schemes and for national TB programmes to improve equitable access to care.

Citing Articles

Out-of-pocket payment and catastrophic health expenditure of tuberculosis patients in accessing care at public-private mix clinics in Myanmar, 2022.

Khaing M, U N, Maw L, Arkar H, Naing S, Thet M Infect Dis Poverty. 2024; 13(1):81.

PMID: 39497185 PMC: 11536886. DOI: 10.1186/s40249-024-01248-7.


Determinant of catastrophic costs associated with treatment for rifampicin-resistant TB in households in the Republic of Moldova.

Ciobanu A, Plesca V, Doltu S, Manea M, Domente L, Dadu A IJTLD Open. 2024; 1(6):266-273.

PMID: 39021450 PMC: 11249656. DOI: 10.5588/ijtldopen.23.0608.


TB and poverty: the effect of rifampicin-resistant TB on household income.

Ciobanu A, Plesca V, Doltu S, Manea M, Domente L, Dadu A IJTLD Open. 2024; 1(4):181-188.

PMID: 38988411 PMC: 11231822. DOI: 10.5588/ijtldopen.23.0607.


Economic burden and coping mechanisms by tuberculosis treatment supporters: a mixed method approach from Bono Region, Ghana.

Bio R, Akweongo P, Koduah A, Adomah-Afari A BMC Health Serv Res. 2024; 24(1):148.

PMID: 38291448 PMC: 10826066. DOI: 10.1186/s12913-024-10611-1.


Trends of Private Drugs' Sales and Costs Incurred by Patients on Anti-tuberculosis Drugs in Selected Districts of Jharkhand (2022): Results From Sub-national TB-Free Certification.

Sinha R, Rana R, Kujur A, Jahnavi G, Kumar M, Venugopal V Cureus. 2023; 15(10):e47296.

PMID: 38021489 PMC: 10656432. DOI: 10.7759/cureus.47296.